China Huntington's Disease Drugs Market Report 2023 to 2030

China Huntington's Disease Drugs Market Analysis

$ 3999

China Huntington's Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease especially rise in disease modifying therapies, incentives provided by regulatory authorities like orphan drug designations. Some of the key players in the global Huntington's Disease Drugs Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals, Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Drugs(Australia) and som biotech (spain).

ID: IN10CNRD095 CATEGORY: Rare Diseases GEOGRAPHY: China AUTHOR: Sakshi Mantri

Buy Now

China Huntington's Disease Drugs Market Analysis Summary

China Huntington's Disease Drugs Market is valued at around $0.068 Mn in 2022 and is projected to reach $0.28 Mn by 2030, exhibiting a CAGR of 19% during the forecast period 2023-2030.

In some parts of the brain, Huntington's disease (HD), an inherited condition, causes the progressive degeneration and death of nerve cells (neurons). Multiple parts of the brain are affected by the disease, including regions linked to the control of voluntary (intentional) movement.

One of the primary reasons influencing the market expansion for therapies for the condition is the onset of Huntington's disease symptoms, which increases the need for HD treatments. While there is currently no cure for HD, several drugs are used to manage its symptoms and improve the quality of life for individuals with the condition. Drugs used in the treatment of this disease are Tetrabenazine (Xenazine) an FDA-approved medication for the treatment of HD-associated chorea, which is the involuntary movements often seen in individuals with HD. It helps to reduce the severity of chorea and improve motor control. Deutetrabenazine (Austedo): Deutetrabenazine is another medication approved for the treatment of chorea associated with Huntington's disease. Antipsychotics are used to manage symptoms of psychosis like Risperidone and olanzapine. Antidepressants like selective serotonin reuptake inhibitors are also used. Muscle relaxants and sleep aids are also used . Some of the key players in the global Huntington's Disease Drugs Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals, Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Drugs(Australia) and som biotech (Spain).

Market Dynamics

Market Drivers

The market for treating Huntington's disease continues to expand due to a variety of causes, such as an increase in the incidence of the illness and a rise in the need for novel drug types to treat the disease's symptoms. Clinical studies and a robust drug pipeline are two other aspects in the Huntington's disease treatment market that are anticipated to support the industry's expected rise. Government initiatives to increase awareness of disease: Governmental organizations constantly roll out new initiatives, campaigns, and beneficiary programmes all over the world to raise public awareness of this ailment and tell patients about their available treatment options. As a result of these efforts, which are predicted to raise the number of cases of the disease that are diagnosed, the demand for cutting-edge drugs is anticipated to rise. Increasing Healthcare Expenditure the market for Huntington's Disease drugs is expanding as a result of rising healthcare spending in both developed and developing nations. This demand is fueling the development of novel drug types to treat the disease's symptoms.

Growing Interest in Personalised Medicine: In the years to come, it is anticipated that the interest in individualized medicine will continue to fuel the development of Clinical studies and a robust drug pipeline for Huntington's disease treatment.

Market Restraints

Strict regulatory hurdles and a lack of licenced drugs may prevent the market from growing:

Effectively two drugs that only treat or manage the disease's symptoms rather than its actual reason have received approval for treatment. If chorea, one of a patient's primary and earliest physical symptoms, is neglected, it gets worse with time. Companies must submit to strict regulations from all around the world in order to obtain a licence for their products.

Limited Availability of Drugs and lack of awareness about the disease

Discontinuation of clinical trials

In March 2021, F. Hoffmann-La Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of tominersen in manifest HD. This conclusion was made on the basis of findings of an unblinded Independent Data Monitoring Committee's (iDMC) pre-planned examination of data from the phase III research.

All these act as market growth restraints.

Key players

Roche Ionis Pharmaceuticals PTC Therapeutics uniQure ProBioGen Stealth Biotherapeutics CoA Therapeutics Orchard Therapeutics CHDI Foundation Shire

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For China Huntington's Disease Drugs Market

By Treatment:

Symptomatic Treatment
Disease-Modifying Treatment
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Diagnosis

MRI
CT Scan
Genetic Testing
Others

By Route of Administration

Oral
Parenteral
Others

By End-Users

Hospitals
Homecare
Specialty Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.